Presentation

Pegascy’s activity consists in developing, in oncology, molecules in phase ½ and 2 (i.e. after preclinical trials, toxicity, dosage and a first contact with humans validated), in-house or under license, with teams of dedicated French and European researchers, alone or in partnership, and to position them on treatments of rare and/or pediatric or female cancers or any other type of cancer for which there are no therapeutic solutions and/or which are neglected by Pharmas.

Contact

ap@pegascy-group.com